Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 24, 2020updated 01 Nov 2021 7:15am

Agilent unveils nanoparticle dissolution testing solution

Agilent Technologies has introduced the new NanoDis System to address the pharma industry’s need for compliant, semi-automated testing of nanoparticle drug formulations.

Agilent Technologies has introduced the new NanoDis System to address the pharma industry’s need for compliant, semi-automated testing of nanoparticle drug formulations.

The system combines Agilent instrumentation and software, helping customers to meet 21 CFR Part 11 and other regulations through its application.

NanoDis System for nanoparticle dissolution testing also provides a dedicated workflow that is automatable and auditable.

NanoDis System, designed alongside nanoparticle manufacturer MyBiotech’s Dr Emre Türeli, aids R&D formulation chemists in bringing new formulations into manufacturing faster.

It also helps manufacturing teams to deliver consistent batches of QC-passed new drug products ready for commercial sale in an automated and compliant manner.

Agilent Technologies Liquid Phase Separation division global marketing associate vice-president Michael Frank said: “Agilent’s introduction of the NanoDis System is significant in that it is the first nanoparticle testing solution that allows methods to be easily transferred from R&D to QC, supporting scientists in meeting the requirements of United States Pharmacopeia (USP).

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

“The NanoDis System can be universally implemented, therefore ensuring that our customers’ global laboratory locations deliver the same results every time.

“Additionally, the NanoDis System is an end-to-end, single-vendor solution that is fully supported by a dedicated global team.”

Though many lifesaving drugs are currently in development using nanoparticles for targeted drug delivery, from a dissolution testing perspective, nanoparticles are complex to work with.

These kinds of dosage forms help to improve patient care, as well as treatment outcomes especially in oncology and cardiology patients, as they lower side-effects and better drug solubility and bioavailability.

Nanoparticle testing is a critical regulatory need for developing, manufacturing and QC of medical drug dosage forms.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU